Plus Therapeutics Surges on FDA Clearance for Childhood Brain Cancer Treatment

Plus Therapeutics shares are trading higher after receiving FDA clearance for its Investigational New Drug application using REYOBIQ for the treatment of childhood brain cancer, supported by a $3 million grant from the U.S. Department of Defense.